JP2011515497A5 - - Google Patents

Download PDF

Info

Publication number
JP2011515497A5
JP2011515497A5 JP2011502076A JP2011502076A JP2011515497A5 JP 2011515497 A5 JP2011515497 A5 JP 2011515497A5 JP 2011502076 A JP2011502076 A JP 2011502076A JP 2011502076 A JP2011502076 A JP 2011502076A JP 2011515497 A5 JP2011515497 A5 JP 2011515497A5
Authority
JP
Japan
Prior art keywords
expression product
patient
level
hematological proliferative
proliferative disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011502076A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011515497A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/038462 external-priority patent/WO2009120905A2/en
Publication of JP2011515497A publication Critical patent/JP2011515497A/ja
Publication of JP2011515497A5 publication Critical patent/JP2011515497A5/ja
Withdrawn legal-status Critical Current

Links

JP2011502076A 2008-03-26 2009-03-26 骨髄性血液学的増殖性疾患と関連する免疫グロブリンおよび/またはToll様受容体タンパク質ならびにその使用 Withdrawn JP2011515497A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3970108P 2008-03-26 2008-03-26
US61/039,701 2008-03-26
PCT/US2009/038462 WO2009120905A2 (en) 2008-03-26 2009-03-26 Immunoglobulin and/or toll-like receptor proteins associated with myelogenous haematological proliferative disorders and uses thereof

Publications (2)

Publication Number Publication Date
JP2011515497A JP2011515497A (ja) 2011-05-19
JP2011515497A5 true JP2011515497A5 (cg-RX-API-DMAC7.html) 2013-05-23

Family

ID=41114735

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011502076A Withdrawn JP2011515497A (ja) 2008-03-26 2009-03-26 骨髄性血液学的増殖性疾患と関連する免疫グロブリンおよび/またはToll様受容体タンパク質ならびにその使用

Country Status (5)

Country Link
US (4) US8709715B2 (cg-RX-API-DMAC7.html)
EP (2) EP2271673B1 (cg-RX-API-DMAC7.html)
JP (1) JP2011515497A (cg-RX-API-DMAC7.html)
CN (1) CN102046660A (cg-RX-API-DMAC7.html)
WO (3) WO2009120905A2 (cg-RX-API-DMAC7.html)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2472856B (en) * 2009-08-21 2012-07-11 Cantargia Ab IL1-RAP modulators and uses thereof
DK2510010T3 (en) 2009-12-10 2015-12-14 Hoffmann La Roche Antibodies that bind to human CSF1R extracellular domain 4 and their use
RU2617971C2 (ru) 2010-03-05 2017-04-28 Ф.Хоффманн-Ля Рош Аг Антитела против csf-1r человека и их применение
CN102918061B (zh) 2010-03-05 2016-06-08 霍夫曼-拉罗奇有限公司 针对人csf-1r的抗体及其用途
JP5940093B2 (ja) 2011-01-19 2016-06-29 カンタージア アクチエボラーグ 抗il−1rap抗体及びヒトを処置するためのそれらの使用
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
US9873918B2 (en) 2011-08-11 2018-01-23 Albert Einstein College Of Medicine, Inc. Treatment of acute myeloid leukemia and myelodysplastic syndromes
MX356337B (es) 2011-12-15 2018-05-23 Hoffmann La Roche Anticuerpos contra csf-1r humano y sus usos.
US10196614B2 (en) 2012-09-18 2019-02-05 University Of Washington Through Its Center For Commercialization Compositions and methods for antigen targeting to CD180
US20150315279A1 (en) * 2012-12-21 2015-11-05 Cellerant Therapeutics, Inc. Antibodies that bind membrane-bound il1rap
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
WO2015014376A1 (en) * 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
UA122479C2 (uk) 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
PL3099717T3 (pl) 2014-01-31 2019-10-31 Novartis Ag Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie
CN106573976B (zh) * 2014-02-06 2020-05-05 耶达研究及发展有限公司 抗cd84抗体、包含所述抗体的组合物及其用途
GB201403875D0 (en) 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
EA201691765A1 (ru) 2014-03-14 2016-12-30 Новартис Аг Молекулы антител против lag-3 и их применения
GB201413913D0 (en) 2014-08-06 2014-09-17 Cantargia Ab Novel antibodies and uses thereof
EP3191126B1 (en) 2014-09-13 2020-05-13 Novartis AG Combination therapies of alk inhibitors
US11708608B2 (en) 2014-11-10 2023-07-25 Genentech, Inc. Therapeutic and diagnostic methods for IL-33-mediated disorders
JP6929771B2 (ja) 2014-11-10 2021-09-01 ジェネンテック, インコーポレイテッド 抗インターロイキン−33抗体及びその使用
CA3218106A1 (en) * 2015-03-06 2016-09-15 The Board Of Regents Of The University Of Texas System Anti-lilrb antibodies and their use in detecting and treating cancer
CA2980460A1 (en) * 2015-04-13 2016-10-20 Five Prime Therapeutics, Inc. Combination therapy for cancer
CN108026172B (zh) 2015-06-26 2022-04-29 赛诺菲生物技术公司 单克隆抗il-1racp抗体
US20180340025A1 (en) 2015-07-29 2018-11-29 Novartis Ag Combination therapies comprising antibody molecules to lag-3
BR112018008908A2 (pt) 2015-11-02 2018-11-27 Janssen Pharmaceutica Nv anticorpos anti-il1rap, moléculas de ligação ao antígeno biespecíficas que se ligam il1rap e cd3, e seus usos
CN108495651A (zh) 2015-12-17 2018-09-04 诺华股份有限公司 抗pd-1的抗体分子及其用途
WO2017191627A1 (en) * 2016-05-02 2017-11-09 Ramot At Tel-Aviv University Ltd. Antibodies to interleukin 13 receptor alpha-1 (il-13r alpha 1) and uses thereof
EP3241845A1 (en) 2016-05-06 2017-11-08 MAB Discovery GmbH Humanized anti-il-1r3 antibodies
KR102543118B1 (ko) 2016-05-27 2023-06-14 아게누스 인코포레이티드 항-tim-3 항체 및 이의 사용 방법
CN106831998B (zh) * 2016-06-22 2020-09-15 徐州医科大学 一种人il1rap特异性car及其应用
US20190248893A1 (en) 2016-07-14 2019-08-15 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
EP3504239B1 (en) 2016-08-25 2024-05-29 F. Hoffmann-La Roche AG Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent
US10253371B2 (en) * 2016-08-29 2019-04-09 National Guard Health Affairs Method of treating leukemia based on gene expression of clock genes
CA3084459A1 (en) 2016-10-16 2018-04-19 Cellerant Therapeutics, Inc. Anti-il1-rap antibodies
CN110072553B (zh) 2016-12-22 2023-09-15 豪夫迈·罗氏有限公司 在抗pd-l1/pd1治疗失败之后抗csf-1r抗体与抗pd-l1抗体组合对肿瘤的治疗
EP3401332A1 (en) 2017-05-08 2018-11-14 MAB Discovery GmbH Anti-il-1r3 antibodies for use in inflammatory conditions
WO2018231827A1 (en) 2017-06-12 2018-12-20 Bluefin Biomedicine, Inc. Anti-il1rap antibodies and antibody drug conjugates
US20210309752A1 (en) * 2018-08-03 2021-10-07 The Trustees Of Indiana University Methods for targeting, inhibiting, and treating a tumoral microenvironment
TW202021618A (zh) 2018-08-17 2020-06-16 美商23與我有限公司 抗il1rap抗體及其使用方法
WO2020146795A1 (en) * 2019-01-11 2020-07-16 Omeros Corporation Methods and compositions for treating cancer
EP4118114A1 (en) 2020-03-13 2023-01-18 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
JP2023553641A (ja) * 2020-12-17 2023-12-25 アストラゼネカ アクチボラグ 抗il5r抗体製剤
CN113238061B (zh) * 2021-07-09 2021-10-01 中南大学湘雅医院 以cd180阴性b细胞指示重症肌无力病情的试剂盒及应用
CN113408480B (zh) * 2021-07-13 2022-09-30 上海交通大学医学院附属瑞金医院 基于骨髓细胞形态学的血液疾病人工智能辅助诊断系统
US12054552B2 (en) 2022-09-21 2024-08-06 Sanofi Biotechnology Humanized anti-IL-1R3 antibody and methods of use
CN119786008B (zh) * 2024-11-13 2025-11-14 南阳市中心医院 基于血液中生物标志物预测烟雾病的临床决策支持方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2145278C (en) 1992-09-25 2009-03-10 Commonwealth Scientific And Industrial Research Organisation Target binding polypeptide
PE64396A1 (es) 1995-01-23 1997-01-28 Hoffmann La Roche Proteina accesoria del receptor de la interleucina 1
US6974682B1 (en) * 1996-08-26 2005-12-13 Human Genome Sciences, Inc. Soluble interleukin-1 receptor accessory molecule
US6280955B1 (en) * 1997-12-16 2001-08-28 Tularik Inc. Interleukin-1 receptor accessory proteins, nucleic acids and methods
PT2857516T (pt) * 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
US7049095B2 (en) * 2000-10-31 2006-05-23 Immunex Corporation DNA encoding IL-1 receptor accessory protein
WO2005019258A2 (en) * 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2005043168A2 (en) * 2003-11-04 2005-05-12 Roche Diagnostics Gmbh Method for distinguishing aml-specific flt3 length mutations from tkd mutations
NZ551180A (en) * 2004-06-01 2009-10-30 Genentech Inc Antibody drug conjugates and methods
RU2007130722A (ru) * 2005-02-16 2009-03-27 Вайет (Us) Способы и устройства для диагностики, прогнозирования и выбора лечения лейкоза
WO2006110593A2 (en) 2005-04-07 2006-10-19 Macrogenics, Inc. Biological targets for the diagnosis, treatment and prevention of cancer
US20060252073A1 (en) * 2005-04-18 2006-11-09 Regents Of The University Of Michigan Compositions and methods for the treatment of cancer
AU2006264567A1 (en) * 2005-05-05 2007-01-11 Valorisation Hsj, Societe En Commandite Cytokine receptor modulators and uses thereof
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20090215992A1 (en) * 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
US7560530B1 (en) * 2006-07-20 2009-07-14 Schering Corporation IL-33 receptor
CA2711370C (en) * 2008-01-15 2017-06-13 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
JP2012516445A (ja) * 2009-01-27 2012-07-19 ホロジック,インコーポレイテッド 体液における新生児敗血症の検出のためのバイオマーカー
US8647623B2 (en) * 2009-04-10 2014-02-11 Kyowa Hakko Kirin Co., Ltd Method for treatment of blood tumor using anti-TIM-3 antibody
GB2472856B (en) * 2009-08-21 2012-07-11 Cantargia Ab IL1-RAP modulators and uses thereof
CN103079644B (zh) * 2010-06-11 2017-02-15 协和发酵麒麟株式会社 抗tim‑3抗体
US20120201746A1 (en) * 2010-12-22 2012-08-09 Abbott Laboratories Half immunoglobulin binding proteins and uses thereof
US20120195900A1 (en) * 2010-12-22 2012-08-02 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
JP5940093B2 (ja) 2011-01-19 2016-06-29 カンタージア アクチエボラーグ 抗il−1rap抗体及びヒトを処置するためのそれらの使用
WO2012142391A1 (en) 2011-04-15 2012-10-18 Merck Patemt Gmbh Anti- il-1r1 inhibitors for use in cancer
JP2014527398A (ja) 2011-06-21 2014-10-16 オンコファクター コーポレイション がんの療法および診断のための組成物および方法
US9873918B2 (en) 2011-08-11 2018-01-23 Albert Einstein College Of Medicine, Inc. Treatment of acute myeloid leukemia and myelodysplastic syndromes

Similar Documents

Publication Publication Date Title
JP2025020283A (ja) 血液悪性腫瘍を処置するための抗lag-3抗体
JP7480248B2 (ja) 腫瘍を処置するための抗lag-3抗体と抗pd-1抗体との組合せ
Linley et al. Lectin binding to surface Ig variable regions provides a universal persistent activating signal for follicular lymphoma cells
KR102416144B1 (ko) 환자에서 항-cd19 치료법의 치료 이익의 예측 방법
KR20140031905A (ko) 다발성 골수종 환자에 대한 bcma-기본 계층화 및 치료법
JP2017079753A (ja) CD19xCD3二重特異性抗体を投与するための投与計画
Chavez et al. Targeting the inducible T-cell costimulator (ICOS) in patients with relapsed/refractory T-follicular helper phenotype peripheral T-cell and angioimmunoblastic T-cell lymphoma
JP2023083424A (ja) 血液悪性腫瘍に対するcd47標的化治療のための投与パラメータ
Ribas et al. Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion
Yin et al. RG7212 anti-TWEAK mAb inhibits tumor growth through inhibition of tumor cell proliferation and survival signaling and by enhancing the host antitumor immune response
Sotomayor et al. Clinical roundtable monograph: CD30 in lymphoma: its role in biology, diagnostic testing, and targeted therapy
KR20230038318A (ko) 불응성 호지킨 림프종에서의 니볼루맙을 사용한 pd-1 차단
CN119798437A (zh) 一种dlbcl患者亚组的奥滨尤妥珠单抗治疗
WO2012142411A1 (en) Systems and methods for detecting hent1 expression in hematological disorders
Shree et al. A phase I clinical trial adding OX40 agonism to in situ therapeutic cancer vaccination in patients with low-grade B-cell lymphoma highlights challenges in translation from mouse to human studies
JP2018528213A5 (cg-RX-API-DMAC7.html)
Ladányi et al. Local immune parameters as potential predictive markers in head and neck squamous cell carcinoma patients receiving induction chemotherapy and cetuximab
Hock et al. Functional effects of immune complexes formed between pembrolizumab and patient-generated anti-drug antibodies
Schwickart et al. Evaluation of assay interference and interpretation of CXCR4 receptor occupancy results in a preclinical study with MEDI 3185, a fully human antibody to CXCR 4
WO2018200473A1 (en) Detection and targeting of tumor-promoting neutrophils cross-reference to related applications
JP6571660B2 (ja) 抗体の分析
JP6195716B2 (ja) 抗癌剤耐性診断マーカー
AU2024247883A1 (en) Methods of treating melanoma using an anti-ctla4 antibody
EP4302092A1 (en) Novel biomarkers and uses thereof
HK40103499A (en) Dosing parameters for cd47 targeting therapies to hematologic malignancies